secwatch.observer — SEC 8-K summary
======================================

Issuer:     NOVAVAX INC (NVAX)
CIK:        0001000694
Form:       8-K
Filed at:   2024-02-28T23:59:59+00:00
Accession:  0001000694-24-000009
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Novavax Q4 revenue $291M, full-year net loss $545M; guides 2024 revenue $800M-$1B
--------------------------------------------------------------------------------

- Q4 2023 revenue $291M (down 18% YoY); full-year revenue $984M (down 51% from $2B in 2022).
- Full-year 2023 net loss $545M vs $658M in 2022; operating expenses cut 41% ($1.1B reduction).
- Cash $584M at Dec 31, 2023, down from $1.3B a year earlier; raised $110M via ATM offerings in Q4.
- FY2024 guidance: total revenue $800M-$1B, combined R&D+SG&A $700-$800M; Q1 2024 revenue expected ~$100M.
- Announced Gavi settlement; plan to start Phase 3 COVID-flu combo trial in H2 2024 with potential 2026 launch.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1000694/000100069424000009/0001000694-24-000009-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1000694/000100069424000009/nvax-20240228.htm
  HTML page:      https://secwatch.observer/filing/0001000694-24-000009

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer